R&D News | pharmaphorum

News

More claudin buzz as Alentis raises $105m

Swiss biotech Alentis Therapeutics has raised a very respectable $105 million in third-round financing that will be dedicated to the development of its Claudin-targeting d

News

Biogen buys into Denali’s amyloid beta programme

Biogen has taken up an option on a technology developed by Denali that it thinks could help improve the safety and efficacy of amyloid-targeting drugs for Alzheimer’s dise

News

Novo Nordisk, Aspect sign $2.6bn diabetes cell therapy deal

Novo Nordisk has put $75 million down on the table to partner Canadian biotech Aspect Biosystems’ cell-based therapies for diabetes and obesity.

News

FDA slaps clinical hold on Merck’s MS drug evobrutinib

Germany’s Merck KGaA said this morning that the FDA has placed a partial clinical hold on its multiple sclerosis drug candidate evobrutinib, vying to become a new oral the

News

Elizabeth Holmes heading for prison as appeal fails

Disgraced former biotech chief Elizabeth Holmes will start an 11-year prison sentence at the end of this month, after a federal judge denied her request to remain free whi

News

Moderna’s flu vaccine trial delayed by case numbers

Moderna’s aspiration to become a player in the seasonal influenza vaccine market has hit a hurdle – likely a delay rather than anything more serious – but its stock has st

More claudin buzz as Alentis raises $105m

Biogen buys into Denali’s amyloid beta programme

Novo Nordisk, Aspect sign $2.6bn diabetes cell therapy deal

FDA slaps clinical hold on Merck’s MS drug evobrutinib

Elizabeth Holmes heading for prison as appeal fails

Moderna’s flu vaccine trial delayed by case numbers

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks